Market capitalization | $302.92m |
Enterprise Value | $254.93m |
P/E (TTM) P/E ratio | 19.08 |
EV/FCF (TTM) EV/FCF | 23.50 |
EV/Sales (TTM) EV/Sales | 1.65 |
P/S ratio (TTM) P/S ratio | 1.96 |
P/B ratio (TTM) P/B ratio | 1.21 |
Revenue growth (TTM) Revenue growth | 6.01% |
Revenue (TTM) Revenue | $154.57m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
2 Analysts have issued a Kamada Ltd forecast:
2 Analysts have issued a Kamada Ltd forecast:
Dec '23 | |
Current assets | 170 170 |
Fixed assets | 185 185 |
Total Assets | 355 355 |
Dec '23 | |
Equity | 244 244 |
Debt capital | 111 111 |
Total Capital | 355 355 |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Kamada Ltd. engages in the development and production of pharmaceutical products. It operates through the Proprietary Products segment and the Distribution segment. The Proprietary Products segment covers the development, manufacture, and sale of plasma-derived protein therapeutics products. The Distribution segment covers the supply of plasma-based products for clinical use. The company was founded by David Tsur and Ralf Hahn on December 13, 1990 and is headquartered in Rehovot, Israel.
Head office | Israel |
CEO | Amir London |
Employees | 378 |
Founded | 1990 |
Website | www.kamada.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.